Healthcare News | BioTuesdays by Kilmer Lucas IR

Markets

Analysts cut Acutus Medical PT to $8 and $10

Analysts for BTIG and Canaccord Genuity reduced their price targets for Acutus Medical (NASDAQ:AFIB) to $8 from $20 and to $10 from $18, respectively, but maintain their “buy” ratings, after the company reported third...

November 12, 2021

Developments

Anti-cancer mechanism of Hepion’s CRV431 to be featured at liver meeting

Results from a study conducted by Dr. Philippe Gallay’s research group at The Scripps Research Institute examining the anti-tumor mechanism of Hepion Pharmaceuticals’ (NASDAQ:HEPA) lead drug candidate, CRV431, will be...

November 10, 2021

Markets

Ladenburg cuts Achieve Life Sciences PT to $50 from $80

Ladenburg Thalmann lowered its price target for Achieve Life Sciences (NASDAQ:ACHV) to $50 from $80, but retained a “buy” rating, citing dilution as well as a reduction in the projected price level of future financings...

November 10, 2021

Developments

Cognetivity Neurosciences presents new results at AD conference

Cognetivity Neurosciences (CSE:CGN; OTCQB:CGNSF; FWB:1UB) presented significant new results demonstrating the capabilities of its Integrated Cognitive Assessment (ICA) platform at the Clinical Trials on Alzheimer’s...

November 9, 2021

Developments

Soricimed, Mount Allison University to collaborate on novel biopesticide solution

Closely-held Soricimed Biopharma and Dr. Vett Lloyd, a professor in the Biology Department at Mount Allison University and head of the Lloyd Tick Lab, are collaborating to design a species-specific, microbial...

November 9, 2021

Developments

BerGenBio presents bemcentinib data in NSCLC; receives FDA fast track

BerGenBio ASA (OSE:BGBIO) will deliver an e-poster presentation at the online Society for Immunotherapy of Cancer meeting with preclinical and clinical data suggesting that bemcentinib restored response to anti-PD-1...

November 9, 2021

Developments

POINT Biopharma, IONETIX in Ac-225 supply agreement

POINT Biopharma Global (NASDAQ:PNT) and IONETIX, a leading cyclotron technology and isotope manufacturing company, entered into a long-term supply agreement for actinium-225 (Ac-225) to support POINT’s validation, drug...

November 9, 2021

Developments

UNITY posts positive Phase 1 data in advanced vascular eye disease

UNITY Biotechnology (NASDAQ:UBX) announced positive 24-week data from its Phase 1 single ascending dose safety study of UBX1325 in patients with advanced disease from diabetic macular edema (DME) or wet age-related...

November 9, 2021

Developments

RNADD in exclusive license for RNA-based molecular lateral flow assay technology

RNA Disease Diagnostics (RNADD) secured an exclusive global license to a rapid ribonucleic acid-based molecular lateral flow assay (LFA) technology jointly owned by the University of Maryland, Baltimore (UMB) and the...

November 9, 2021

Developments

Sustained anti-pruritic effect of Titan’s TP-2021 implant featured at Neuroscience conference

In a presentation at the Society for Neuroscience 2021 meeting, Ben Land, Ph.D., research assistant professor at the University of Washington’s Department of Pharmacology, reported additional positive data from an...

November 8, 2021

Markets

AGP cuts T2 Biosystems PT to 88 cents from $1.25

Alliance Global Partners reduced its price target for T2 Biosystems (NASDAQ:TTOO) to 88 cents from $1.25 and maintained a “neutral” rating after the company reported mixed third quarter results. The stock closed at 79...

November 8, 2021

Markets

Analysts start Lucid Diagnostics at buy: PTs $14, $18

Analysts for BTIG and Canaccord Genuity launched coverage of Lucid Diagnostics (NASDAQ:LUCD) with “buy” ratings and price targets of $14 and $18, respectively. The stock closed at $9.52 on Oct. 5. Lucid recently...

November 8, 2021

Analysts cut Acutus Medical PT to $8 and $10

Anti-cancer mechanism of Hepion’s CRV431 to be featured at liver meeting

Ladenburg cuts Achieve Life Sciences PT to $50 from $80

Cognetivity Neurosciences presents new results at AD conference

Soricimed, Mount Allison University to collaborate on novel biopesticide solution

BerGenBio presents bemcentinib data in NSCLC; receives FDA fast track

POINT Biopharma, IONETIX in Ac-225 supply agreement

UNITY posts positive Phase 1 data in advanced vascular eye disease

RNADD in exclusive license for RNA-based molecular lateral flow assay technology

Sustained anti-pruritic effect of Titan’s TP-2021 implant featured at Neuroscience conference

AGP cuts T2 Biosystems PT to 88 cents from $1.25

Analysts start Lucid Diagnostics at buy: PTs $14, $18

General

More

Sign up for the BioTuesdays weekly newsletter